Search Results - "Hirata, J."

Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices by Nooka, A.K., Nabhan, C., Zhou, X., Taylor, M.D., Byrtek, M., Miller, T.P., Friedberg, J.W., Zelenetz, A.D., Link, B.K., Cerhan, J.R., Dillon, H., Sinha, R., Shenoy, P.J., Levy, D., Dawson, K., Hirata, J.H., Flowers, C.R.

“…Because follicular lymphoma (FL) patients have heterogeneous outcomes, the FL international prognostic index (FLIPI) was developed to risk-stratify patients…”
Get full text

The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers by Goto, T, Takano, M, Hirata, J, Tsuda, H

“…The role of transcriptional factor FOXO1 in the mechanism of drug-resistance in ovarian cancer has not been elucidated. In ovarian cancer cell lines, FOXO1…”
Get full text

Pola‐R‐CHP versus R‐CHOEP in young patients with high‐risk diffuse large B‐cell lymphoma by Lenz, G., Tilly, H., Ziepert, M., Altmann, B., Craine, V., Yan, M., Herbaux, C., Frontzek, F., Nickelsen, M., Hirata, J., Sahin, D., Lee, C., Morschhauser, F., Schmitz, N.

Get full text

Cause of death and prognosis of patients (pts) with primary refractory disease, and prognosis of pts reaching PFS24: Descriptive analysis of POLARIX by Herbaux, C., Dietrich, S., McMillan, A., Thieblemont, C., Gonzalez‐Barca, E., Pinto, A., Fogliatto, L., Matasar, M., Lee, C., Hernandez, J., Hirata, J., Ho, R., Launonen, A., Boissard, F.

Get full text

CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE POLARIX STUDY by Herrera, A. F., Tracy, S., Sehn, L. H., Jardin, F., Lenz, G., Trněný, M., Salles, G., Flowers, C. R., Tilly, H., Sharman, J. P., Friedberg, J. W., Balasubramanian, S., Raghavan, V., Hirata, J., Lee, C., Jiang, Y., Morschhauser, F.

Get full text

Subgroup analysis of elderly patients (pts) with diffuse large B‐cell lymphoma (DLBCL) in the Phase 3 POLARIX study by Hu, B., Reagan, P. M., Sehn, L. H., Sharman, J., Hertzberg, M., Zhang, H., Kim, A., Herbaux, C., Molina, L., Maruyama, D., Smolewski, P., Stenner, F., Craine, V., Kothari, R., Hirata, J., Sahin, D., Sugidono, M., Lee, C., Tilly, H.

Get full text

Time‐to‐Event Analysis of Polatuzumab Vedotin‐Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens by Lu, D, Gillespie, WR, Girish, S, Agarwal, P, Li, C, Hirata, J, Chu, Y‐W, Kagedal, M, Leon, L, Maiya, V, Jin, JY

“…Polatuzumab vedotin, an antibody‐drug conjugate containing monomethyl auristatin E, was associated with an incidence of grade ≥2 peripheral neuropathy (PN) of…”
Get full text

Patient‐ versus clinician‐reported symptoms in the POLARIX study by Thompson, C. A., Mehta‐Shah, N., Flowers, C., Salles, G., Tilly, H., Chua, N., Casasnovas, R., Miall, F., Kim, T. M., Tsai, C., Nasta, S., Lee, S. T., Craine, V., Campinha‐Bacote, A., Hirata, J., Lee, C., Sugidono, M., Friedberg, J. W.

Get full text

IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO POLA‐R‐CHP TREATMENT REDUCES TUMOR MICROENVIRONMENT DEPENDENCY by Morschhauser, F., Hatzi, K., Lenz, G., Herrera, A. F., Flowers, C. R., Trněný, M., Burke, J. M., Hou, J., Staber, P. B., Hawkes, E. A., Izutsu, K., Le Gouill, S., Belada, D., Tucci, A., Yan, M., Harris, W., Hirata, J., Lee, C., Jiang, Y., Jardin, F.

Get full text

POLATUZUMAB VEDOTIN + OBINUTUZUMAB + VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF A PHASE 1B/2 TRIAL by Bannerji, R., Yuen, S., Phillips, T., Arthur, C., Isufi, I., Marlton, P., Seymour, J. F., Corradini, P., Molinari, A., Gritti, G., Emmons, R., Hirata, J., Musick, L., Saha, S., Croft, B., Flowers, C.

Get full text

High-temperature-required protein A2 as a predictive marker for response to chemotherapy and prognosis in patients with high-grade serous ovarian cancers by Miyamoto, M, Takano, M, Iwaya, K, Shinomiya, N, Goto, T, Kato, M, Suzuki, A, Aoyama, T, Hirata, J, Nagaoka, I, Tsuda, H, Furuya, K

“…Background: High-temperature-required protein A2 (HtrA2), a protein relating with apoptosis in a caspases-dependent and non-dependent manner, has been reported…”
Get full text

Kinetics of solid-state polymorphic transition of glycine in mechano-chemical processing by Matsuoka, M., Hirata, J., Yoshizawa, S.

“…The kinetics of solid-state polymorphic transition of the stable polymorph of glycine (Form γ) to an unstable Form α were studied using a planetary ball mill…”
Get full text

POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) + LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PHASE IB/II INTERIM ANALYSIS by Diefenbach, C., Kahl, B., Banerjee, L., McMillan, A., Ramchandren, R., Miall, F., Briones, J., Cordoba, R., Gonzalez‐Barca, E., Panizo, C., Hirata, J., Chang, N., Musick, L., Abrisqueta, P.

Get full text

P1190: OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMENTS IN UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA FROM THE POLARIX TRIAL by Morschhauser, F., Jiang, Y., Jardin, F., Herrera, A. F., Sehn, L. H., Herbaux, C., Flowers, C., Phillips, T., López Guillermo, A., Diefenbach, C., Gregory, G. P., Kim, A., Barbui, A. M., Balasubramanian, S., Harris, W., Hirata, J., Paulson, J. N., Lee, C., Lenz, G.

Get full text

P1189: INITIAL SAFETY RUN‐IN RESULTS OF THE PHASE III POLARGO TRIAL: POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA by McMillan, A., Haioun, C., Sancho, J.‐M., Viardot, A., Rodriguez Izquierdo, A., Donato Martin, E. M., García‐Sancho, A. M., Sandoval‐Sus, J., Tilly, H., Vandenberghe, E., Hirata, J., Choudhry, P., Chang, Y. M., Musick, L., Matasar, M.

Get full text

P1191: ANALYSIS OF PERIPHERAL NEUROPATHY USING CLINICIAN‐ AND PATIENT‐REPORTED OUTCOMES IN THE POLARIX STUDY by Trněný, M., Fogliatto, L., Gardner, F., Flinn, I., Larouche, J.‐F., Haioun, C., Canales, M., Goto, H., Hajek, R., Salles, G., Qiu, J., Campinha‐Bacote, A., Yan, M., Kothari, R., Man, G., Sahin, D., Hirata, J., Lee, C., Tilly, H., Flowers, C.

Get full text

P1192: ASIA SUBPOPULATION ANALYSIS FROM THE PHASE III POLARIX TRIAL by Song, Y., Jin, J., Tilly, H., Zhang, H., Cao, J., Feng, J., Zhang, L., Rai, S., Goto, H., Terui, Y., Kim, W. S., Shin, H.‐J., Gau, J.‐P., Tsai, C.‐H., Sharman, J. P., Bu, L., Hirata, J., Lee, C., Izutsu, K., Zhu, J.

Get full text

Integrated Two‐Analyte Population Pharmacokinetic Model for Antibody–Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling by Lu, D, Gibiansky, L, Agarwal, P, Dere, RC, Li, C, Chu, Y‐W, Hirata, J, Joshi, A, Jin, JY, Girish, S

“…An integrated pharmacokinetics (PK) model that simultaneously describes concentrations of total antibody (Tab) and antibody‐conjugated monomethyl auristatin E…”
Get full text

POLA‐R‐CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA by Tilly, H., Sharman, J., Bartlett, N., Morschhauser, F., Haioun, C., Munoz, J., Chen, A., Lamy, T., Wang, L., Penuel, E., Hirata, J., Lee, C., Salles, G.

Get full text

Effect of high pressure gaseous carbon dioxide on the germination of bacterial spores by Furukawa, S., Watanabe, T., Tai, T., Hirata, J., Narisawa, N., Kawarai, T., Ogihara, H., Yamasaki, M.

“…Effect of high pressure gaseous carbon dioxide treatment (HGCT) at 6.5 MPa, 35 °C on the germination of bacterial spores was investigated. Germination of…”
Get full text